Barclays PLC Acquires 71,301 Shares of STAAR Surgical (NASDAQ:STAA)

Barclays PLC grew its stake in STAAR Surgical (NASDAQ:STAA) by 349.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,707 shares of the medical instruments supplier’s stock after acquiring an additional 71,301 shares during the period. Barclays PLC owned 0.19% of STAAR Surgical worth $3,406,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. XTX Topco Ltd acquired a new position in STAAR Surgical during the third quarter valued at approximately $508,000. State Street Corp raised its stake in shares of STAAR Surgical by 0.5% during the 3rd quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock worth $72,092,000 after purchasing an additional 10,430 shares in the last quarter. Quarry LP acquired a new stake in shares of STAAR Surgical in the 3rd quarter valued at approximately $50,000. Polar Asset Management Partners Inc. grew its stake in shares of STAAR Surgical by 44.3% in the third quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock valued at $6,271,000 after buying an additional 51,800 shares in the last quarter. Finally, HighTower Advisors LLC acquired a new position in STAAR Surgical during the third quarter worth $336,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Insider Transactions at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 53,500 shares of STAAR Surgical stock in a transaction dated Monday, December 16th. The stock was bought at an average price of $24.24 per share, with a total value of $1,296,840.00. Following the completion of the transaction, the insider now owns 10,821,931 shares in the company, valued at $262,323,607.44. The trade was a 0.50 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.00% of the stock is owned by corporate insiders.

STAAR Surgical Stock Down 2.6 %

STAAR Surgical stock opened at $24.17 on Tuesday. The company’s 50-day moving average price is $28.17 and its two-hundred day moving average price is $34.36. The stock has a market cap of $1.19 billion, a P/E ratio of 54.93 and a beta of 0.59. STAAR Surgical has a twelve month low of $23.72 and a twelve month high of $52.68.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Canaccord Genuity Group cut their target price on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research note on Monday, December 9th. Stephens raised STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus cut their price objective on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, August 26th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $42.83.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.